Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab Add-on to Brief Education in Migraine With Medication Overuse Headache
2024-510729-24-00Phase 4Completed
- Sponsor
- Lundbeck
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 4, randomised, double-blind trial in migraine, chronic migraine and medication overuse headache (MOH) comparing Eptinezumab arm with Placebo arm (2 arms). Primary endpoint: Change from baseline in the number of monthly headache days (MHDs). Started Apr 2024; status: completed.
02
Drugs
eptinezumab
03
Conditions
migrainechronic migrainemedication overuse headache (MOH)
Beyond the preview
Go deeper on 2024-510729-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510729-24-00.